巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    VolitionRX Limited

    VNRX
    2.370
    0.040
    1.72%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・VolitionRX Limited - 延遲價格・最後更新於 26/05 6:05
    最高位
    2.400
    最低位
    2.370
    開市價
    --
    前收市價
    2.330
    成交量(千)
    0.13
    成交額(百萬)
    0.00
    買入
    2.360
    賣出
    2.420
    每手股數
    --
    市值(百萬)
    150.63
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.140 - 2.080
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    VolitionRX Limited
    證券代碼
    VNRX.US
    所屬板塊
    Diagnostics & Research
    公司業務
    VolitionRX Ltd is a US-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.
    發行量
    53775261
    公司總部
    13215 Bee Cave Parkway, Suite 125, Galleria Oaks B
    公司網址
    https://www.volition.com
    公司電郵
    investorrelations@volition.com
    公司電話
    +1 646 650-1351
    暫無內容

    關於

    VolitionRX Limited(VNRX.US)所屬的行業板塊為Diagnostics & Research。
    VolitionRX Ltd is a US-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers. The development pipeline includes assays to be used for symptomatic patients or asymptomatic populations. The company has developed more than 30 blood-based assays to detect specific biomarkers. It also develops Nucleosomics tests for several major cancers including CRC, pancreatic, lung and aggressive prostate. In addition, the company engages in the process of developing HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to help decide the appropriate therapy.
    詳細公司背景可參考: https://www.volition.com